Nutraceuticals as Emerging Antiangiogenic Agents

Pankaj Gupta

doi:10.4172/2167-1206.1000e116

ISSN: 2573-4555

Journal of Traditional Medicine & Clinical Naturopathy

Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.

Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business

Nutraceuticals as Emerging Antiangiogenic Agents

Pankaj Gupta^*
School of Medical & Allied Sciences, K. R. Mangalam University, Gurgaon, Haryana, India
Corresponding Author :	Dr. Pankaj Gupta Assistant Professor School of Medical & Allied Sciences K. R. Mangalam University Sohna Road, Gurgaon-122103 Haryana, India Tel: +91-11-9818256122 E-mail: gupta.aiims@gmail.com
Received: August 25, 2015; Accepted: August 26, 2015; Published: September 02, 2015
Citation: Gupta P. (2015) Nutraceuticals as Emerging Antiangiogenic Agents. J Homeop Ayurv Med 4:e116. doi:10.4172/2167-1206.1000e116
Copyright: © 2015 Gupta P. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Related article at Pubmed, Scholar Google

Visit for more related articles at Journal of Traditional Medicine & Clinical Naturopathy

View PDF Download PDF

Editorial

Nutraceuticals provide us with nutritional needs along with health benefits by preventing the pathological conditions from arising. Therefore, nutraceuticals engrave a great promise to improve human health and nutrition. The term nutraceutical emerged from the terms, nutrition and pharmaceutical and involves food that provides health benefits either by preventing the onset of disease or via treating the disease. Nutraceuticals have already been used for the treatment of diabetes, depression, arthritis, inflammation and presently they have been explored for their effect on angiogenesis that is associated with a broad array of pathological conditions such as cancer, diabetes, age related macular degeneration, retinopathy of prematurity etc. Angiogenesis, the formation of new blood vessels from the pre-existing ones, plays an important role in cancer formation and therefore the development of antiangiogenic agents to block new blood vessels growth will possibly inhibit the progression of tumour growth. Presently, nutraceuticals are being looked upon for their role as antiangiogenic agents.

Several components from food resources have shown potent antiangiogenic efficacy via different mechanisms of action. The antiangiogenic nutraceuticals include flavones that mediate antiangiogenic effect via inhibition of HUVEC (human Umbilical vein endothelial cells) proliferation. Other examples include yellow coloured flavouring agent curcumin that show antiangiogenic effect via inhibition of the pro-angiogenic growth factors such as VEGF (vascular endothelial growth factor) and bFGF (basic fibroblast growth factor), antiangiogenic polyphenols from green tea and red wine cause scavenging of reactive oxygen species, genistein inhibits VEGF and matrix metalloproteinase induced angiogenesis while resveratrol exhibits antiangiogenic action via inhibiting the VEGF induced proliferation of new blood vessels. The above examples depict the inherent potential of nutraceuticals and demand their further explorations for curing the diseases associated with angiogenesis.

Nutraceuticals are not only effective in curing the diseases associated with angiogenesis but also offer a cheaper and accessible mode of antiangiogenic therapy. The current antiangiogenic therapies include the usage of monoclonal antibodies such as bevacizumab that are relatively costly so as to be afforded by a common man. This situation can be overcome by the emergence of nutraceuticals as newer antiangiogenic agents that would treat angiogenesis related diseases at a relatively lesser cost in comparison to the presently available antiangiogenic therapies. Therefore, the development of nutraceuticals as antiangiogenic agents would not only provide cheaper and alternative therapies for treating diseases associated with angiogenesis but would also benefit the patients with their nutritive value.